Data from clinical trials submitted to regulatory authorities showed that rimonabant caused depressive disorders or mood alterations in up to 10% of subjects and suicidal ideation in around 1%, and in Europe it was contraindicated for people with any psychiatric disorder, including depressed or suicidal people.<ref name=EMAlabel/>

 


 
Additionally, nausea and upper respiratory tract infections were very common (occurring in more than 10% of people) adverse effects; common adverse effects (occurring in between 1% and 10% of people) included [[gastroenteritis]], anxiety, irritability, insomnia and other sleep disorders, hot flushes, diarrhea, vomiting, dry or itchy skin, tendonitis, muscle cramps and spasms, fatigue, flu-like symptoms, and increased risk of falling.

 


 
The FDA's advisory committee raised concerns that based on animal data, it appeared that the [[therapeutic window]] with regard to CNS toxicity, and specifically seizures was almost nonexistent; the therapeutic dose and the dose that caused seizures in animals appeared to be the same.<ref name=Moreira2009/><ref>{{cite web|title=FDA Briefing Document NDA 21-888 Zimulti (rimonabant) Tablets, 20|url=https://www.fda.gov/ohrms/dockets/ac/07/briefing/2007-4306b1-fda-backgrounder.pdf|publisher=FDA|date=June 13, 2007}}</ref><ref>{{cite web|last1=Davis-Bruno|first1=Karen|title=Nonclinical Overview: CNS Toxicity with Rimonabant|url=www.fda.gov/ohrms/dockets/ac/07/slides/2007-4306s1-09-FDA-Bruno.ppt|publisher=FDA, Division of Metabolism & Endocrinology Products|date=June 13, 2007}}</ref>

 


 
When the EMA reviewed [[postmarketing surveillance]] data, it found that the risk of psychiatric disorders in people taking rimonabant was doubled.<ref name=Moreira2009/>

 

